Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...
PARIS — Early implantation of an intra-aortic balloon pump (IABP) in patients with decompensated heart failure (HF) and low output provided more effective treatment than inotropic agents in a small ...
Early inflation Balloon inflates before aortic valve closes – the left ventricle is therefore forced to empty against an inflated balloon. There is an increase in afterload, potentially raising ...
Continuing the trajectory seen at 30 days and 1 year, the long-term data from the IABP-SHOCK II trial reported today show no survival benefit for intra-aortic balloon pump (IABP) use in acute MI ...
Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...
Compared with the years 2000-2009, cardiac deaths and case fatalities in U.S. marathon and half-marathon runners have come down significantly. (JAMA) People with zero of five classic cardiovascular ...
Announcing a new article publication for Cardiovascular Innovations and Applications journal. An intra-aortic balloon pump (IABP) is the device most frequently used as a bridge to surgical repair in ...
AMSTERDAM, The Netherlands— In patients undergoing early revascularization for myocardial infarction (MI) complicated by cardiogenic shock, use of an intra-aortic balloon pump (IABP) does not reduce ...
PARIS -- Intra-aortic balloon pumps (IABP) didn't significantly improve outcomes for patients with ischemia persisting well after percutaneous coronary intervention (PCI) for a large acute ST-segment ...
Please provide your email address to receive an email when new articles are posted on . The FDA announced it has designated a recall of intra-aortic balloon pumps by Datascope/Getinge as class I, the ...
In the multicentre, open-label, randomized, controlled trial IABP-SHOCK II, the previously reported 30-day data demonstrated no early mortality reduction with intra-aortic balloon pump (IABP) use in ...